Inventor · disambiguated record
Peter U. Park
Also filed as: PARK PETER · PARK PETER U
30 granted patents·27 pending applications·464 citations·filing 2007–2024
97Inventor score
Files withBICYCLETX LTD15MERSANA THERAPEUTICS INC9IMMUNOGEN INC7ORUM THERAPEUTICS INC6DECKERT JUTTA5
Top patents by PatentIndex Score
57 records- 0197US11542304B2Multimeric bicyclic peptide ligandsBICYCLETX LTD·Filed 2020·Granted Jan 3, 2023·14 cites·20 claims
- 0296US12049520B2Bicyclic peptide ligands specific for CD137BICYCLETX LTD·Filed 2022·Granted Jul 30, 2024·14 cites·24 claims
- 0396US11912792B2Bicyclic peptide ligands specific for nectin-4BICYCLETX LTD·Filed 2022·Granted Feb 27, 2024·14 cites·18 claims
- 0496US11453702B2Bicyclic peptide ligands specific for Nectin-4BICYCLETX LTD·Filed 2021·Granted Sep 27, 2022·16 cites·21 claims
- 0596US11180531B2Bicyclic peptide ligands specific for Nectin-4BICYCLETX LTD·Filed 2019·Granted Nov 23, 2021·18 cites·24 claims
- 0696US10875894B2Multimeric bicyclic peptide ligandsBICYCLETX LTD·Filed 2019·Granted Dec 29, 2020·26 cites·29 claims
- 0796US9738720B2Monoclonal antibodies against HER2 epitope and methods of use thereofMERSANA THERAPEUTICS INC·Filed 2016·Granted Aug 22, 2017·10 cites·30 claims
- 0895US11453703B2Heterotandem bicyclic peptide complexesBICYCLETX LTD·Filed 2019·Granted Sep 27, 2022·15 cites·17 claims
- 0995US11261214B2Bicyclic peptide ligand specific for CD137BICYCLETX LTD·Filed 2018·Granted Mar 1, 2022·16 cites·25 claims
- 1095US8765917B2CD37-binding molecules and immunoconjugates thereofDECKERT JUTTA·Filed 2011·Granted Jul 1, 2014·31 cites·26 claims
- 1194US10947317B2NaPi2b-targeted antibody-drug conjugates and methods of use thereofMERSANA THERAPEUTICS INC·Filed 2017·Granted Mar 16, 2021·9 cites·15 claims
- 1294US9555112B2Monoclonal antibodies against HER2 epitope and methods of use thereofMERSANA THERAPEUTICS INC·Filed 2015·Granted Jan 31, 2017·13 cites·42 claims
- 1394US9346887B2CD37-binding molecules and immunoconjugates thereofIMMUNOGEN INC·Filed 2013·Granted May 24, 2016·12 cites·41 claims
- 1494US8153765B2Anti-CD38 antibodies for the treatment of cancerPARK PETER U·Filed 2007·Granted Apr 10, 2012·164 cites·30 claims
- 1593US11613560B2Bicyclic peptide ligands specific for OX40BICYCLETX LTD·Filed 2020·Granted Mar 28, 2023·15 cites·26 claims
- 1693US8790649B2EGFR-binding molecules and immunoconjugates thereofSETIADY JULIANTO·Filed 2011·Granted Jul 29, 2014·26 cites·37 claims
- 1790US10202460B2CD37-binding molecules and immunoconjugates thereofDEBIOPHARM INT SA·Filed 2016·Granted Feb 12, 2019·7 cites·22 claims
- 1889US12459974B2Bicyclic peptide ligands specific for Nectin-4BICYCLETX LTD·Filed 2024·Granted Nov 4, 2025·0 cites·11 claims
- 1989US11466095B2CD37-binding molecules and immunoconjugates thereofDEBIOPHARM INT SA·Filed 2018·Granted Oct 11, 2022·3 cites·21 claims
- 2089US10556958B2CD37-binding molecules and immunoconjugates thereofDEBIOPHARM INT SA·Filed 2016·Granted Feb 11, 2020·7 cites·20 claims
- 2189US9447189B2CD37-binding molecules and immunoconjugates thereofDECKERT JUTTA·Filed 2012·Granted Sep 20, 2016·13 cites·27 claims
- 2289US2025066489A1Monoclonal antibodies against her2 epitope and methods of use thereofMERSANA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2388US2024400616A1Bicyclic peptide ligands specific for nectin-4BICYCLETX LTD·Filed 2024·Application pending·0 cites
- 2487US2025216392A1Novel anti-cd38 antibodies for the treatment of cancerSANOFI AVENTIS US LLC·Filed 2024·Application pending·0 cites
- 2585US9233171B2Method of treatment of tumors that are resistant to EGFR antibody therapies by EGFR antibody cytotoxic agent conjugateSETIADY JULIANTO·Filed 2012·Granted Jan 12, 2016·4 cites·51 claims
- 2685US9173961B2CD20 antibodies and uses thereofDECKERT JUTTA·Filed 2011·Granted Nov 3, 2015·8 cites·32 claims
- 2782US2023265197A1Monoclonal antibodies against her2 epitope and methods of use thereofMERSANA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2880US9808528B2Protein-polymer-drug conjugates and methods of using sameMERSANA THERAPEUTICS INC·Filed 2015·Granted Nov 7, 2017·2 cites·20 claims
- 2980US9125896B2EGFR-binding molecules and immunoconjugates thereofIMMUNOGEN INC·Filed 2013·Granted Sep 8, 2015·3 cites·39 claims
- 3079US2025059236A1Bicyclic peptide ligands specific for cd137BICYCLETX LTD·Filed 2024·Application pending·0 cites
- 3175US12378288B2Multimeric bicyclic peptide ligandsBICYCLETX LTD·Filed 2022·Granted Aug 5, 2025·0 cites·29 claims
- 3274US11518812B2Monoclonal antibodies against HER2 epitope and methods of use thereofMERSANA THERAPEUTICS INC·Filed 2019·Granted Dec 6, 2022·0 cites·14 claims
- 3373US2021269480A1Bicyclic peptide ligands specific for nectin-4BICYCLETX LTD·Filed 2019·Application pending·0 cites
- 3472US9238690B2Non-antagonistic EGFR-binding molecules and immunoconjugates thereofSETIADY JULIANTO·Filed 2011·Granted Jan 19, 2016·1 cites·38 claims
- 3572US2020408765A1Novel anti-cd38 antibodies for the treatment of cancerSANOFI SA·Filed 2020·Application pending·0 cites
- 3669US9314522B2Antitumors combinations containing antibodies recognizing specifically CD38 and bortezomibDECKERT JUTTA·Filed 2011·Granted Apr 19, 2016·3 cites·14 claims
- 3769US2017313778A1Monoclonal antibodies against her2 epitope and methods of use thereofMERSANA THERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 3867US2023008076A1Heterotandem bicyclic peptide complexesBICYCLETX LTD·Filed 2022·Application pending·0 cites
- 3963US2020270361A1Cd37-binding molecules and immunoconjugates thereofDEBIOPHARM INT SA·Filed 2020·Application pending·0 cites
- 4062US2023211008A1ConjugatesORUM THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4161US2021301031A1Napi2b-targeted antibody-drug conjugates and methods of use thereofMERSANA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4260US2017343550A1Novel anti-cd38 antibodies for the treatment of cancerSANOFI SA·Filed 2017·Application pending·0 cites
- 4359US2025304563A1Activators of effector t cellsORUM THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 4456US2025144230A1Linkers for use in antibody drug conjugatesORUM THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4555US2012156218A1Novel anti-cd38 antibodies for the treatment of cancerPARK PETER U·Filed 2012·Application pending·0 cites
- 4655US2011262454A1Novel anti-cd38 antibodies for the treatment of cancerSANOFI AVENTIS·Filed 2011·Application pending·0 cites
- 4754US2024252671A1Neodegrader-anti-cd33 antibody conjugatesORUM THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4854US2023338564A1Neodegrader conjugatesORUM THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4953US2025090681A1Neodegrader conjugatesORUM THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 5051US9175086B2CD20 antibodies and uses thereofDECKERT JUTTA·Filed 2011·Granted Nov 3, 2015·0 cites·37 claims
Showing the top 50 of 57 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Peter U. Park files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →